Find and Join

News Logo

• Let’s talk about that Lilly announcement

  There’s been plenty of coverage of Eli Lilly’s announcement this week that it will sell vials of Zepbound directly to consumers at a discount. But the company seems to have left out a few important caveats. read more →

• Our response to the op-ed in The Hill

  The Hill published an editorial by Dr. Kenneth McCall titled “Fake, unsafe weight-loss drugs are a worsening public health dilemma” in which he makes unfounded claims about pharmacy compounding. Here’s the response from our CEO. read more →

• The shortage ends … then what? (Find out at CCH) 

  We’ve added a new session to the Compounders on Capitol Hill lineup. Don’t miss the discussion of what’s on many a compounder’s (and regulators’ … and reporters’...) mind. read more →

• A new bronze corporate patron

  A big welcome to Ro, APC’s newest tier-level corporate patron! read more →

• Education (and CE) from USP

  For the fourth year in a row, USP will be holding a hybrid live/virtual workshop dedicated to improving the quality of compounding. read more →

• Compounding post-Chevron

  At least three issues affecting pharmacy compounding might be affected by the overturning of the decades-old “Chevron doctrine.” read more →

• 503B sourcing: our state-by-state analysis

  Do you work for one of APC’s PFMs? If you’re with a Pharmacy/Facility Member, you’ve got access to a new resource. read more →

• What we’ll be talking about at CCH

  When we get together on Capitol Hill to meet with legislators and their staffs, as much as we’d like to talk about a half-dozen issues (easily!), we’re going to be focusing on the three most important.  read more →

More News

There’s been plenty of coverage of Eli Lilly’s announcement this week that it will sell vials of Zepbound directly to consumers at a discount. But the company seems to have left out a few important caveats, as STAT News pointed out. 

Lilly simultaneously raised the “discounted” price it offers people whose insurance doesn’t cover Zepbound from $550 to $650 a month. Oh, and those Zepbound vials? That’s only the starter dose. For people to continue to use it — as they have to — the only option is the (hard to find) injector pens at full price.

The media turns to APC

If you happened to read the Lilly/Zepbound story on CBS News, you might have noticed that the story quoted our CEO Scott Brunner, who called Lilly’s move “great news for patients” — at least theoretically. 

“We’ll be eager to see whether Lilly’s direct-to-patient approach actually works and how quickly FDA will judge that supply is once again sufficient to meet demand. It’s that calculation that will determine whether the drug comes off the shortage list,” APC CEO Scott Brunner said in a statement to CBS MoneyWatch.

Inside Health Policy also quoted Scott in its story about Lilly’s announcement: “It’s a much more rational and care-focused response to the remarkable demand for their drug than the lawsuits and cease-and-desist letters Lilly has been raining down on compounding pharmacies.”